Fiscal 2013 Guidance
The Company expects to close the acquisition of Vortex Medical by the end of October. In fiscal year 2013, the acquisition is expected to add approximately $1 million in sales, reduce operating income by approximately $5 million, have negligible impact on EBITDA, and reduce EPS by approximately $0.09 on a GAAP and Non-GAAP basis.
|Sales ($ in mils.) (a)||361 – 364||361 – 364|
|Pro Forma Sales Growth (b)||5%||5%|
|Gross Margin (c)||50-51%||51-52%|
|Operating Income ($ in mils.) (d)||13 – 15||29 – 31|
|EBITDA ($ in mils.) (d) (e), a Non- GAAP measure||44 – 45||60 – 61|
|EPS ($) (f)||0.12 - 0.14||0.40 - 0.42|
|a) Quarterly calendarization is expected to approximate 23%/24%/25%/28% of the annual amount.|
|b) Fiscal year 2012 pro forma combined sales excluding LC Beads is $344.3 million.|
|c) Includes $3.4 million for amortization of inventory basis step-up and $1.2 million for the QCTA/FDA remediation programs, which are excluded in Adjusted Non-GAAP, and $2.9 million for the medical device tax with effect from January 1, 2013, which is included in GAAP and Adjusted Non-GAAP.|
|d) Adjusted result reflects an estimated $16 million in acquisition-related and restructuring costs, which include amortization of inventory basis step-up, accelerated asset depreciation, transaction-related professional fees, employment severance costs, QCTA/FDA remediation programs, and the closure of the U.K. manufacturing facility. Quarterly calendarization of the $16 million will approximate $7 million/$5 million/$2 million/$2 million.|
|e) $17 million in amortization, $8 million in depreciation, and $4 million in purchase accounting related to Vortex Medical are excluded from both measures.|
|f) Approximately 36 million diluted shares outstanding and a 37% tax rate.|
"Our goal remains to exit the fiscal year positioned to generate double-digit top- and bottom-line growth over the long term," added Mr. DeVivo.